

FILE 'REGISTRY' ENTERED AT 12:32:47 ON 07 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 SEP 2009 HIGHEST RN 1180919-38-3
DICTIONARY FILE UPDATES: 6 SEP 2009 HIGHEST RN 1180919-38-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10595882-2.str



chain nodes :
11 12 13 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-12 8-11 12-13 13-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :
3-12 5-7 6-10 7-8 8-9 8-11 9-10 12-13 13-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:CLASS 16:Atom

L1 STRUCTURE UPLOADED

=> S 11 SSS SAM
SAMPLE SEARCH INITIATED 12:33:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 81544 TO ITERATE


2.5% PROCESSED 2000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1613872 TO 1647888
PROJECTED ANSWERS: 3221 TO 4933

L2 5 SEA SSS SAM L1


=> D scan

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-[4-[1,2-dihydro-7-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-quinolinyl]-2-thiazolyl]-N-methyl-
MF C24 H24 N6 O4 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2,3-Quinoxalinedione, 1-cyclohexyl-1,4-dihydro-6-nitro-7-[3-[(4-phenyl-1-piperazinyl)methyl]-1H-pyrrol-1-yl]-
MF C29 H32 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2-Thiophenesulfonamide, N-[4-[1,2-dihydro-7-[(4-methyl-1-piperidinyl)carbonyl]-2-oxo-3-quinolinyl]-2-thiazolyl]-N-methyl-
 MF C24 H24 N4 O4 S3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2,3-Quinoxalinedione, 6-[amino(2-iodophenyl)methyl]-1,4-dihydro-
 MF C15 H12 I N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)ethyl]-
 MF C13 H12 N4 O





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\STNEXP\Queries\10595882-3.str



chain nodes :
11 12 13 16 18
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-12 7-18 8-11 12-13 13-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-12 5-7 6-10 7-8 7-18 8-9 8-11 9-10 12-13 13-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 12:Atom 13:CLASS 16:Atom 18:CLASS

L3 STRUCTURE UPLOADED

=> S 13 sss sam

SAMPLE SEARCH INITIATED 12:37:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 41839 TO ITERATE

4.8% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


10 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 824554 TO 849006
PROJECTED ANSWERS: 3316 TO 5050

L4 10 SEA SSS SAM L3


=> D scan

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 7-[(2-methyl-1-piperidinyl)carbonyl]-3-[5-[(2-thienylsulfonyl)methyl]-1,2,4-thiadiazol-3-yl]-
MF C23 H22 N4 O4 S3




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Thiophenesulfonamide, N-[5-[4-amino-1,2-dihydro-7-[(4-methyl-1-piperidinyl)carbonyl]-2-oxo-3-quinolinyl]-1,2,4-thiadiazol-3-yl]-N-methyl-
MF C23 H24 N6 O4 S3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2,3-Quinoxalinedione, 6-[amino(2-iodophenyl)methyl]-1,4-dihydro-
MF C15 H12 I N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C27 H31 N5 O3 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-[5-(4-amino-1,2-dihydro-7-[2-(3-methyl-1-piperidinyl)ethyl]-2-oxo-3-quinolinyl]-1,2,4-thiadiazol-3-yl]-N-methyl-
MF C25 H29 N7 O3 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinesulfonamide, N-[2-[1,2-dihydro-2-oxo-7-(1-piperidinylcarbonyl)-3-

MF quinolinyl]-4-thiazolyl]-N-methyl-
C24 H23 N5 O4 S2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 4-amino-7-[2-(2-methyl-1-piperidinyl)ethyl]-3-[3-(4-pyridinyl)-1,2,4-thiadiazol-5-yl]-
MF C24 H26 N6 O S




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 7-[2-(2-methyl-1-piperidinyl)methyl]-3-[4-(4-pyridinyl)-2-thiazolyl]-
MF C24 H24 N4 O S




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Pyridinesulfonamide, N-[2-[1,2-dihydro-2-oxo-7-[2-(1-pyrrolidinyl)ethyl]-3-quinolinyl]-4-thiazolyl]-N-methyl-
MF C24 H25 N5 O3 S2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



L4 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 3-[2-[(phenylsulfonyl)methyl]-4-thiazolyl]-7-(1-piperazinylmethyl)-
MF C24 H24 N4 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\STNEXP\Queries\10595882-5.str



```
chain nodes :  
11 12 13 16 18 19  
ring nodes :  
1 2 3 4 5 6 7 8 9 10  
chain bonds :  
3-12 7-18 8-11 9-19 12-13 13-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10  
exact/norm bonds :  
3-12 5-7 6-10 7-8 7-18 8-9 8-11 9-10 9-19 12-13 13-16  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6
```

G1:C,N

```
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:CLASS 16:Atom 18:CLASS 19:CLASS  
Element Count :  
Node 19: Limited  
C,C1-6
```

L5 STRUCTURE UPLOADED

```
=> S 15 sss sam  
SAMPLE SEARCH INITIATED 12:44:01 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 41839 TO ITERATE
```

```
4.8% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**  
BATCH **COMPLETE**  
PROJECTED ITERATIONS: 824554 TO 849006  
PROJECTED ANSWERS: 0 TO 0
```

L6 0 SEA SSS SAM L5

```
=> S 15 sss full  
FULL SEARCH INITIATED 12:45:08 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 838410 TO ITERATE
```


```
97.3% PROCESSED 816071 ITERATIONS 186 ANSWERS  
100.0% PROCESSED 838410 ITERATIONS 186 ANSWERS  
SEARCH TIME: 00.00.21
```

L7 186 SEA SSS FUL L5

=> D scan

```
L7 186 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 2(1H)-Quinolinone, 3-ethyl-5-methoxy-7-[(4-(2-methoxyphenyl)-1-piperazinyl)methyl]-
```


MF C24 H29 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L7 186 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 3-ethyl-7-[4-(4-pyridinyl)-1-piperazinyl]methyl-
MF C21 H24 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 186 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-(4-morpholinyl)ethyl]-
MF C17 H22 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file zcaplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

195.96

196.18

FILE 'ZCPLUS' ENTERED AT 12:46:12 ON 07 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 7 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 6 Sep 2009 (20090906/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

ZCplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> d his

(FILE 'HOME' ENTERED AT 12:32:33 ON 07 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:32:47 ON 07 SEP 2009

L1 STRUCTURE UPLOADED
L2 5 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 10 S L3 SSS SAM
L5 STRUCTURE UPLOADED
L6 0 S L5 SSS SAM
L7 186 S L5 SSS FULL

FILE 'ZCPLUS' ENTERED AT 12:46:12 ON 07 SEP 2009

=> S 17
L8 10 L7

=> D ibib hitstr 10

L8 ANSWER 10 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:612014 ZCPLUS <<LOGINID::20090907>>

DOCUMENT NUMBER: 113:212014
 ORIGINAL REFERENCE NO.: 113:35835a,35838a
 TITLE: Preparation of (1H-azol-1-ylmethyl)quinolines,
 -quinazolines, and -quinoxalines as drugs
 INVENTOR(S): Freyne, Eddy Jean Edgard; Venet, Marc Gaston;
 Raeymaekers, Alfons Herman Margaretha; Sanz, Gerard
 Charles
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 106 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| EP 371564 | A2 | 19900606 | EP 1989-203014 | 19891128 |
| EP 371564 | A3 | 19910529 | | |
| EP 371564 | B1 | 19950712 | | |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| US 5028606 | A | 19910702 | US 1989-434957 | 19891113 |
| US 5037829 | A | 19910806 | US 1989-435120 | 19891113 |
| CA 2002864 | A1 | 19900529 | CA 1989-2002864 | 19891114 |
| CA 2002864 | C | 19911116 | | |
| DK 8905994 | A | 19900530 | DK 1989-5994 | 19891128 |
| DK 172748 | B1 | 19990628 | | |
| NO 8904734 | A | 19900530 | NO 1989-4734 | 19891128 |
| NO 174509 | B | 19940207 | | |
| NO 174509 | C | 19940518 | | |
| AU 8945646 | A | 19900607 | AU 1989-45646 | 19891128 |
| AU 620946 | B2 | 19920227 | | |
| HU 52498 | A2 | 19900728 | HU 1989-6220 | 19891128 |
| HU 205106 | B | 19920330 | | |
| ZA 8909076 | A | 19910731 | ZA 1989-9076 | 19891128 |
| SU 1780536 | A3 | 19921207 | SU 1989-4742543 | 19891128 |
| IL 92486 | A | 19930708 | IL 1989-92486 | 19891128 |
| ES 2088889 | T3 | 19961001 | ES 1989-203014 | 19891128 |
| FI 101964 | B | 19980930 | FI 1989-5687 | 19891128 |
| FI 101964 | B1 | 19980930 | | |
| CN 1042912 | A | 19900613 | CN 1989-108925 | 19891129 |
| CN 1033752 | C | 19970108 | | |
| JP 02223579 | A | 19900905 | JP 1989-307793 | 19891129 |
| JP 2916181 | B2 | 19990705 | | |
| US 5151421 | A | 19920929 | US 1991-672298 | 19910320 |
| US 5185346 | A | 19930209 | US 1991-704746 | 19910523 |
| US 5268380 | A | 19931207 | US 1992-973871 | 19921110 |
| US 5441954 | A | 19950815 | US 1993-131817 | 19931005 |
| CN 1106004 | A | 19950802 | CN 1994-117801 | 19941102 |
| CN 1036002 | C | 19971001 | | |
| CN 1106005 | A | 19950802 | CN 1994-117802 | 19941102 |
| CN 1036003 | C | 19971001 | | |
| US 5612354 | A | 19970318 | US 1995-409551 | 19950323 |
| PRIORITY APPLN. INFO.: | | | GB 1988-27820 | A 19881129 |
| | | | GB 1988-27821 | A 19881129 |
| | | | GB 1988-27822 | A 19881129 |
| | | | US 1989-434205 | B2 19891113 |
| | | | US 1989-434957 | A3 19891113 |
| | | | US 1991-704746 | A3 19910523 |
| | | | US 1992-973871 | A3 19921110 |
| | | | US 1993-131817 | A3 19931005 |

OTHER SOURCE(S):

MARPAT 113:212014


| | | | |
|----|--------------|--------------|--------------|
| IT | 130346-19-9P | 130346-28-0P | 130346-36-0P |
| | 130346-37-1P | 130346-38-2P | 130346-40-6P |
| | 130346-44-0P | 130346-54-2P | 130346-57-5P |
| | 130346-60-0P | 130346-61-1P | 130346-64-4P |
| | 130346-67-7P | 130346-70-2P | 130346-71-3P |
| | 130346-74-6P | 130346-75-7P | 130346-78-0P |
| | 130346-80-4P | 130346-92-8P | 130347-24-9P |
| | 130347-27-2P | 130347-29-4P | 130347-38-5P |
| | 130347-40-9P | 130347-76-1P | 130368-35-3P |

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as retinocate metabolism and aromatase inhibitor)


RN 130346-19-9 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-(1H-imidazol-1-ylmethyl)-3-methyl- (CA INDEX NAME)




RN 130346-28-0 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-methyl- (CA INDEX NAME)




RN 130346-36-0 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-37-1 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)ethyl]-3-methyl- (CA INDEX NAME)



RN 130346-38-2 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
(CA INDEX NAME)




RN 130346-40-6 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 130346-39-3

CMF C19 H15 F N4 O



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 130346-44-0 ZCPLUS


CN 2-Quinoxalineacetic acid, 3,4-dihydro-6-(1H-imidazol-1-ylmethyl)-alpha-

methyl-3-oxo-, ethyl ester (CA INDEX NAME)




RN 130346-54-2 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-(cyclopropyl-1H-imidazol-1-ylmethyl)-3-methyl- (CA INDEX NAME)




RN 130346-57-5 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 130346-60-0 ZCPLUS

CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-3-methylbutyl]-3-methyl- (CA INDEX NAME)




RN 130346-61-1 ZCPLUS


CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-(1-methylethyl)- (CA INDEX NAME)




RN 130346-64-4 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)propyl]-3-methyl- (CA INDEX NAME)




RN 130346-67-7 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl- (CA INDEX NAME)




RN 130346-70-2 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX NAME)




RN 130346-71-3 ZCPLUS
 CN 2-Quinoxalinecarboxylic acid, 3,4-dihydro-6-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 130346-74-6 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl(4-methylphenyl)methyl]-3-methyl-
 (CA INDEX NAME)




RN 130346-75-7 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)pentyl]-3-methyl- (CA INDEX
 NAME)




RN 130346-78-0 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl(4-methoxyphenyl)methyl]-3-methyl-
 (CA INDEX NAME)




RN 130346-80-4 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-(1H-imidazol-1-yl-2-thienylmethyl)-3-methyl- (CA
 INDEX NAME)




RN 130346-92-8 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-propyl-
 (CA INDEX NAME)




RN 130347-24-9 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl(4-(1-methylethyl)phenyl)methyl]-3-
 methyl- (CA INDEX NAME)




RN 130347-27-2 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(2-
 methylpropyl)- (CA INDEX NAME)




RN 130347-29-4 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-
 (CA INDEX NAME)




RN 130347-38-5 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-propyl-
 (CA INDEX NAME)



RN 130347-40-9 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-(1-
 methylpropyl)- (CA INDEX NAME)




RN 130347-76-1 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl)-1H-imidazol-1-ylmethyl]-3-propyl-
 (CA INDEX NAME)



RN 130368-35-3 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-methyl-7-[(2-methyl-1-(1H-1,2,4-triazol-1-yl)propyl)-1H-imidazol-1-ylmethyl]-

(CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)

=> D ibib hitstr 1-9


L8 ANSWER 1 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:885718 ZCPLUS <<LOGINID::20090907>>
DOCUMENT NUMBER: 151:173496
TITLE: Fused heterocyclic derivatives as HGF modulators and their preparation and methods of use
INVENTOR(S): Albrecht, Brian K.; Bauer, David; Bellon, Steven; Bode, Christiane M.; Booker, Shon; Boezio, Alessandro; Choquette, Deborah; D'Amico, Erin; Harmange, Jean-Christophe; Hirai, Satoko; Hungate, Randall W.; Kim, Tae-Seong; Lewis, Richard T.; Liu, Longbin; Lohman, Julia; Norman, Mark H.; Potashman, Michelle; Siegmund, Aaron C.; Springer, Stephanie; Stec, Markian; Xi, Ning; Yang, Kevin; Peterson, Emily A.; Romero, Karina; Copeland, Katrina W.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 236pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 2009091374 | A2 | 20090723 | WO 2008-US11724 | 20081014 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 2009124609 | A1 | 20090514 | US 2008-9123 | 20080115 |
| PRIORITY APPLN. INFO.: | | | US 2008-9123 | A2 20080115 |
| | | | US 2006-830882P | P 20060714 |
| | | | US 2007-879034 | A2 20070713 |

OTHER SOURCE(S): MARPAT 151:173496
IT 1151800-61-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused heterocyclic derivs. as HGF modulators useful in the treatment of diseases)

RN 1151800-61-1 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-methyl-7-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methyl]- (CA INDEX NAME)



L8 ANSWER 2 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:588488 ZCPLUS <>LOGINID::20090907>>
 DOCUMENT NUMBER: 150:539755
 TITLE: Fused heterocyclic derivatives as HGF modulators and their preparation and methods of use
 INVENTOR(S): Albrecht, Brian K.; Bauer, David; Bellon, Steven; Bode, Christiane M.; Booker, Shon; Boezio, Alessandro; Choquette, Deborah; D'Amico, Derin; Harmange, Jean-Christophe; Hirai, Satoko; Hungate, Randall W.; Kim, Tae-Seong; Lewis, Richard T.; Liu, Longbin; Lohman, Julia; Norman, Mark H.; Potashman, Michele; Siegmund, Aaron C.; Springer, Stephanie; Stec, Markian; Xi, Ning; Yang, Kevin
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 252pp., Cont.-in-part of U.S. Ser. No. 879,034.
 CODEN: USXSC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 20090124609 | A1 | 20090514 | US 2008-9123 | 20080115 |
| US 20090124612 | A1 | 20090514 | US 2007-879034 | 20070713 |
| WO 200901374 | A2 | 20090723 | WO 2008-US11724 | 20081014 |
| W: AB, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: US 2006-830882P P 20060714

US 2007-879034

A2 20070713

US 2008-9123

A2 20080115

OTHER SOURCE(S):

MARPAT 150:539755


IT 1151800-61-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused heterocyclic derivs. as HGF modulators useful in the treatment of diseases)

RN 1151800-61-1 ZCPLUS

CN 2(1H)-Quinoxalinone, 3-methyl-7-[(6-phenyl-1,2,4-triazolo[4,3-b]pyridazin-3-yl)methyl]- (CA INDEX NAME)



L8 ANSWER 3 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:519324 ZCPLUS <<LOGINID::20090907>>

DOCUMENT NUMBER: 150:472754

TITLE: Quinolinone derivatives as PARP-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Angibaud, Patrick Rene; Marconnet-Decrane, Laurence Francoise Bernadette; Vialard, Jorge Eduardo; Mevellec, Laurence Anne; Meyer, Christophe; Storck, Pierre-Henri

PATENT ASSIGNEE(S): Janssen Pharmaceutica NV, Belg.

SOURCE: PCT Int. Appl., 103pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2009053373 | A1 | 20090430 | WO 2008-EP642443 | 20081022 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: EP 2007-119417 A 20071026


OTHER SOURCE(S): MARPAT 150:472754

IT 1146679-86-8P 1146679-87-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of quinolinone derivs. as PARP1 inhibitors useful in the treatment of PARP-mediated diseases)


RN 1146679-86-8 ZCPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]-, ethyl ester (CA INDEX NAME)



RN 1146679-87-9 ZCPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]-, hydrochloride (19:12) (CA INDEX NAME)




● 12/19 HCl

| | | | |
|----|---------------|---------------|---------------|
| IT | 1146679-77-7P | 1146679-78-8P | 1146679-80-2P |
| | 1146679-81-3P | 1146679-82-4P | 1146679-83-5P |
| | 1146679-84-6P | 1146679-85-7P | 1146679-88-0P |
| | 1146679-91-5P | 1146679-92-6P | 1146679-93-7P |
| | 1146679-95-9P | 1146679-96-0P | 1146679-97-1P |
| | 1146679-98-2P | 1146680-01-4P | 1146680-02-5P |
| | 1146680-03-6P | 1146680-04-7P | 1146680-05-8P |
| | 1146680-06-9P | 1146680-08-1P | 1146680-10-5P |
| | 1146680-11-6P | 1146680-12-7P | 1146680-14-9P |
| | 1146680-15-0P | 1146680-16-1P | 1146680-17-2P |
| | 1146680-19-4P | 1146680-21-8P | 1146680-27-4P |
| | 1146680-28-5P | 1146680-29-6P | 1146680-30-9P |
| | 1146680-31-0P | 1146680-32-1P | 1146680-33-2P |
| | 1146680-34-3P | 1146680-35-4P | 1146680-36-5P |
| | 1146680-37-6P | 1146680-38-7P | 1146680-39-8P |
| | 1146680-40-1P | 1146680-41-2P | 1146680-42-3P |
| | 1146680-43-4P | 1146680-44-5P | 1146680-46-7P |
| | 1146680-47-8P | 1146680-48-9P | 1146680-49-0P |
| | 1146680-50-3P | 1146680-51-4P | 1146680-52-5P |
| | 1146680-53-6P | 1146680-54-7P | 1146680-55-8P |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinolinone derivs. as PARP1 inhibitors useful in the treatment of PARP-mediated diseases)


RN 1146679-77-7 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-(2-pyridinyl)-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 1146679-78-8 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)




RN 1146679-80-2 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 1146679-81-3 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-phenyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 1146679-82-4 ZCPLUS
CN 2(1H)-Quinolinone, 3-methyl-7-[(4-phenyl-1-piperidinyl)methyl]- (CA INDEX NAME)




RN 1146679-83-5 ZCPLUS
 CN 3-Pyridinecarbonitrile, 6-[4-[3-(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)propyl]-1-piperazinyl]-, hydrochloride (20:13) (CA INDEX NAME)




●13/20 HCl


RN 1146679-84-6 ZCPLUS
 CN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-(4-(phenylmethyl)-1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 1146679-85-7 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[3,4-dihydro-2(1H)-isoquinolinyl]carbonyl]-3-ethyl- (CA INDEX NAME)




RN 1146679-88-0 ZCPLUS
 CN 3-Pyridinecarbonitrile, 6-[4-[1-(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)-2-methylpropyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-91-5 ZCPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-((3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-92-6 ZCPLUS
CN 3-Pyridinecarbonitrile, 6-[4-((3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl)-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-93-7 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(4-(2-chlorophenyl)-1-piperazinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 1146679-95-9 ZCPLUS
CN Benzonitrile, 2-[4-[(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)ethyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146679-96-0 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 1146679-97-1 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 1146679-98-2 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(4-(2-methoxyphenyl)-1-piperazinyl)methyl]-3-methyl- (CA INDEX NAME)



RN 1146680-01-4 ZCPLUS
CN 2(1H)-Quinolinone, 3-methyl-7-[(4-(2-pyrimidinyl)-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 1146680-02-5 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-(2-methoxyethyl)-1-piperazinyl)methyl]-
(CA INDEX NAME)




RN 1146680-03-6 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(1S,4S)-5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-3-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1146680-04-7 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-3-ethyl-
(CA INDEX NAME)




RN 1146680-05-8 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-(2-pyrimidinyl)-1-piperazinyl)methyl]-
(CA INDEX NAME)




RN 1146680-06-9 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-(phenylmethyl)-1-piperidinyl)methyl]-


(CA INDEX NAME)




RN 1146680-08-1 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[2-hydroxy-1-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)








RN 1146680-10-5 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[4-(4-pyridinyl)-1-piperazinyl]methyl- (CA INDEX NAME)




RN 1146680-11-6 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[4-(2-pyrazinyl)-1-piperazinyl]methyl- (CA INDEX NAME)




RN 1146680-12-7 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[4-(1H-indazol-3-yl)-1-piperazinyl]methyl- (CA INDEX NAME)




RN 1146680-19-4 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-[(4-(2-phenylethyl)-1-piperazinyl)methyl]-
(CA INDEX NAME)




RN 1146680-21-8 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(4-(3-chlorophenyl)-1-piperazinyl)methyl]-3-ethyl-
(CA INDEX NAME)




RN 1146680-27-4 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(1-[4-(4-chlorophenyl)-1-piperidinyl]ethyl)-3-methyl-
(CA INDEX NAME)




RN 1146680-28-5 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(1-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)ethyl)-3-
methyl- (CA INDEX NAME)




RN 1146680-29-6 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(1-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl)-3-
methyl- (CA INDEX NAME)




RN 1146680-30-9 ZCPLUS
 CN 2(1H)-Quinolinone, 3-methyl-7-[1-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 1146680-31-0 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[1-(4-cyclohexyl-1-piperazinyl)ethyl]-3-methyl- (CA INDEX NAME)




RN 1146680-32-1 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[1-(4-[(2-methoxyethyl)amino]-1-piperidinyl)ethyl]-3-methyl- (CA INDEX NAME)




RN 1146680-33-2 ZCPLUS
 CN 2(1H)-Quinolinone, 3-methyl-7-[1-[4-[3-(trifluoromethyl)-2-pyridinyl]1-piperazinyl]ethyl]- (CA INDEX NAME)




RN 1146680-34-3 ZCPLUS
 CN 2(1H)-Quinolinone, 3-methyl-7-[(4-(2-pyridinyl)-1-piperazinyl)methyl]-
 (CA INDEX NAME)




RN 1146680-35-4 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[1-(4-(3-chlorophenyl)-1-piperazinyl)ethyl]-3-methyl-
 (CA INDEX NAME)




RN 1146680-36-5 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)carbonyl]-3-methyl-
 (CA INDEX NAME)




RN 1146680-37-6 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[(4-(2-chlorophenyl)-1-piperazinyl)carbonyl]-3-methyl-
 (CA INDEX NAME)




RN 1146680-38-7 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-7-(1-pyrrolidinylmethyl)- (CA INDEX NAME)




RN 1146680-39-8 ZCPLUS
CN 5-Pyrimidinecarboxamide, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1146680-40-1 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(1,3-dihydro-2H-isindol-2-yl)methyl]-3-ethyl- (CA INDEX NAME)




RN 1146680-41-2 ZCPLUS
CN 2(1H)-Quinolinone, 3-ethyl-5-methoxy-7-[(4-(2-methoxyphenyl)-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 1146680-42-3 ZCPLUS
CN 2(1H)-Quinolinone, 7-[cyclohexyl(4-phenyl-1-piperidinyl)methyl]-3-methyl-
(CA INDEX NAME)




RN 1146680-43-4 ZCPLUS
CN 3-Pyridinecarbonitrile, 6-[4-[1-(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)-2-methylpropyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-44-5 ZCPLUS
CN Benzonitrile, 2-[4-[cyclohexyl(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-46-7 ZCPLUS
CN 2(1H)-Quinolinone, 3-methyl-7-[1-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 1146680-47-8 ZCPLUS
CN 3-Pyridinecarbonitrile, 6-[4-[(3-ethyl-1,2-dihydro-5-methoxy-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-48-9 ZCPLUS
 CN 3-Pyridinecarbonitrile, 6-[4-[cyclohexyl(1,2-dihydro-3-methyl-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)




RN 1146680-49-0 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[{4-(2-chlorophenyl)-1-piperazinyl}methyl]-3-ethyl-5-methoxy- (CA INDEX NAME)




RN 1146680-50-3 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[cyclohexyl[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-51-4 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[cyclohexyl(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-52-5 ZCPLUS
 CN 2(1H)-Quinolinone, 3-methyl-7-[1-(4-phenyl-1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 1146680-53-6 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[cyclohexyl[4-(2-pyridinyl)-1-piperazinyl]methyl]-3-methyl- (CA INDEX NAME)




RN 1146680-54-7 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[1-(4-(2-chlorophenyl)-1-piperazinyl)ethyl]-3-methyl- (CA INDEX NAME)



RN 1146680-55-8 ZCPLUS
 CN 2(1H)-Quinolinone, 7-[1-(4-(2-chlorophenyl)-1-piperazinyl)cyclohexylmethyl]-3-methyl- (CA INDEX NAME)




IT 1146680-78-5P 1146680-88-7P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prophetic intermediate; preparation of quinolinone derivs. as PARP1 inhibitors useful in the treatment of PARP-mediated diseases)
 RN 1146680-78-5 ZCPLUS
 CN 5-Pyrimidinecarbonyl chloride, 2-[4-[(3-ethyl-1,2-dihydro-2-oxo-7-quinolinyl)methyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1146680-88-7 ZCPLUS
 CN 2(1H)-Quinolinone, 7-(chlorocyclohexylmethyl)-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2009:247530 ZCPLUS <>LOGINID::20090907>>
 DOCUMENT NUMBER: 150:438012
 TITLE: Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas
 AUTHOR(S): Li, Hui-Fang; Lu, Tao; Zhu, Tian; Jiang, Yong-Jun;
 Rao, Sha-Sha; Hu, Li-Ye; Xin, Bo-Tao; Chen, Ya-Dong
 CORPORATE SOURCE: Department of Organic Chemistry, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China
 SOURCE: European Journal of Medicinal Chemistry (2009), 44(3), 1240-1249

CODEN: EJMCAS; ISSN: 0223-5234
 PUBLISHER: Elsevier Masson SAS
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 883829-01-4, NCI 0648594
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas)
 RN 883829-01-4 ZCPLUS
 CN 2-Quinoxalinepropanamide, 6-benzoyl-3,4-dihydro-N-(4-methoxy-2-nitrophenyl)- α ,3-dioxo- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1101739 ZCPLUS <>LOGINID::20090907>>
 DOCUMENT NUMBER: 149:355743
 TITLE: Quinolinone derivatives as PARP and TANK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Vialard, Jorge Eduardo; Angibaud, Patrick Rene; Mevellec, Laurence Anne; Meyer, Christophe; Freyne, Eddy Jean Edgard; Pilatte, Isabelle Noelle Constance; Roux, Bruno; Pasquier, Elisabeth Therese Jeanne; Bourdrez, Xavier Marc; Adelinet, Christophe Denis; Marconnet-Decrane, Laurence Francoise Bernadette; Macritchie, Jacqueline Anne; Duffy, James Edward Stewart; Owens, Andrew Pate; Storck, Pierre-Henri; Poncelet, Virginie Sophie
 PATENT ASSIGNEE(S): Janssen Pharmaceutica NV, Belg.
 SOURCE: PCT Int. Appl., 223pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2008107478 | A1 | 20080912 | WO 2008-EP52764 | 20080307 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2007-103788 A 20070308
US 2007-893680P P 20070308


OTHER SOURCE(S): MARPAT 149:355743

IT 1056889-05-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of quinoline derivs. as PARP and TANK inhibitors useful in the treatment of diseases)

RN 1056889-05-4 ZCPLUS

CN 7-Quinolineacetonitrile, α -(6-bromo-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- α ,3-dimethyl-2-oxo- (CA INDEX NAME)



IT 1056888-99-3P 1056889-00-9P 1056889-01-0P

1056889-02-1P 1056889-03-2P 1056889-04-3P

1056889-06-5P 1056890-39-1P 1056891-80-5P

1056891-81-6P 1056891-82-7P 1056891-83-8P

1056891-84-9P 1056891-85-0P 1056891-86-1P

1056891-87-2P 1056891-88-3P 1056891-89-4P

1056891-90-7P 1056891-91-8P 1056891-93-0P

1056891-94-1P 1056891-95-2P 1056891-99-6P


1056892-00-2P 1056892-01-3P 1056892-05-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinoline derivs. as PARP and TANK inhibitors useful in the treatment of diseases)

RN 1056888-99-3 ZCPLUS

CN 7-Quinolineacetonitrile, α -[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- α ,3-dimethyl-2-oxo-, (aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056889-00-9 ZCPLUS

CN 7-Quinolineacetonitrile, α -[(1R)-5-bromo-2,3-dihydro-1H-inden-1-yl]-

1,2-dihydro- α ,3-dimethyl-2-oxo-, (α R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056889-01-0 ZCPLUS

CN 7-Quinolineacetonitrile, α -[(1R)-5-cyano-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- α ,3-dimethyl-2-oxo-, (α R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056889-02-1 ZCPLUS

CN 7-Quinolineacetonitrile, α -[(7R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl]-3-ethyl-1,2-dihydro- α -methyl-2-oxo-, (α S)-rel- (CA INDEX NAME)


Relative stereochemistry.




RN 1056889-03-2 ZCPLUS

CN 7-Quinolineacetonitrile, α -[(7R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl]-3-ethyl-1,2-dihydro- α -methyl-2-oxo-, (α R)-rel- (CA INDEX NAME)


Relative stereochemistry.




RN 1056889-04-3 ZCPLUS
 CN 7-Quinolineacetonitrile, α -(4-bromo-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- α ,3-dimethyl-2-oxo- (CA INDEX NAME)



RN 1056889-06-5 ZCPLUS
 CN 7-Quinolineacetonitrile, α -(6-cyano-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- α ,3-dimethyl-2-oxo- (CA INDEX NAME)




RN 1056890-39-1 ZCPLUS
 CN 7-Quinolineacetonitrile, α -cyclopropyl-3-ethyl-1,2-dihydro-2-oxo- α -(2-phenoxyethyl)- (CA INDEX NAME)



RN 1056891-80-5 ZCPLUS
 CN 7-Quinolineacetonitrile, α -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-3-ethyl-1,2-dihydro- α -methyl-2-oxo-, (α S)-rel- (CA INDEX)

NAME)


Relative stereochemistry.



RN 1056891-81-6 ZCPLUS

CN 7-Quinolineacetonitrile, α -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-3-ethyl-1,2-dihydro- α -methyl-2-oxo-, (α R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 1056891-82-7 ZCPLUS

CN 7-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-83-8 ZCPLUS


CN 7-Quinolineacetonitrile, α -[(1R)-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- α ,3-dimethyl-2-oxo-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056891-84-9 ZCPLUS
CN 7-Quinolineacetonitrile, α -[(1S)-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- α ,3-dimethyl-2-oxo-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056891-85-0 ZCPLUS
CN 7-Quinolineacetonitrile, α -[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- α ,3-dimethyl-2-oxo-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-86-1 ZCPLUS
CN 7-Quinolineacetonitrile, α ,3-diethyl- α -(6-fluoro-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 1056891-87-2 ZCPLUS
CN 7-Quinolineacetonitrile, α -(4-cyano-2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- α ,3-dimethyl-2-oxo- (CA INDEX NAME)



RN 1056891-88-3 ZCPLUS

CN 7-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-89-4 ZCPLUS

CN 7-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1056891-90-7 ZCPLUS


CN 7-Quinolineacetonitrile, α -[(1R)-2,3-dihydro-1H-inden-1-yl]-1,2-dihydro- α ,3-dimethyl-2-oxo-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056891-91-8 ZCPLUS
CN 7-Quinolineacetonitrile, α -(6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-1,2-dihydro- α ,3-dimethyl-2-oxo-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056891-93-0 ZCPLUS
CN 7-Quinolineacetonitrile, α -(2,3-dihydro-1H-inden-1-yl)-1,2-dihydro- α ,3-dimethyl-2-oxo- (CA INDEX NAME)




RN 1056891-94-1 ZCPLUS
CN 7-Quinolineacetonitrile, α -[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-3-ethyl-1,2-dihydro- α -methyl-2-oxo-, (α R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056891-95-2 ZCPLUS
CN 7-Quinolineacetonitrile, α -[(4R)-3,4-dihydro-2H-1-benzopyran-4-yl]-3-ethyl-1,2-dihydro- α -methyl-2-oxo-, (α S)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056891-99-6 ZCPLUS
 CN 7-Quinolineacetonitrile, α -(2,3-dihydro-6-methoxy-1H-inden-1-yl)-
 α ,3-diethyl-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 1056892-00-2 ZCPLUS
 CN 7-Quinolineacetonitrile, α -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-
 1,2-dihydro- α ,3-dimethyl-2-oxo-, (aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1056892-01-3 ZCPLUS
 CN 7-Quinolineacetonitrile, α -[(1R)-6-bromo-2,3-dihydro-1H-inden-1-yl]-
 1,2-dihydro- α ,3-dimethyl-2-oxo-, (aR)-rel- (CA INDEX NAME)


Relative stereochemistry.




RN 1056892-05-7 ZCPLUS
 CN 7-Quinolineacetonitrile, 1,2-dihydro- α ,3-dimethyl-2-oxo- α -
 (1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




IT 1056887-62-7P 1056887-63-8P 1056887-65-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinoline derivs. as PARP and TANK inhibitors useful in the treatment of diseases)
 RN 1056887-62-7 ZCPLUS
 CN 7-Quinolineacetonitrile, α -(4-cyanophenyl)-3-ethyl-1,2-dihydro-2-oxo- α -(phenylmethyl)- (CA INDEX NAME)



RN 1056887-63-8 ZCPLUS
 CN 7-Quinolineacetonitrile, 3-ethyl-1,2-dihydro-2-oxo- α -phenyl- α -(phenylmethyl)- (CA INDEX NAME)



RN 1056887-65-0 ZCPLUS
 CN 7-Quinolineacetonitrile, α -cyclopropyl-3-ethyl-1,2-dihydro-2-oxo- α -(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:523429 ZCPLUS <>LOGINID::20090907>>
DOCUMENT NUMBER: 143:60002
TITLE: Preparation of 7-phenylalkyl substituted
2-quinolinones and 2-quinoxalinones as
poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome
Emile Georges; Van Dun, Jacobus Alphonsus Josephus;
Somers, Maria Victoria Francisca; Wouters, Walter
Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| WO 2005054209 | A1 | 20050616 | WO 2004-EP13162 | 20041118 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JE, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004295057 | A1 | 20050616 | AU 2004-295057 | 20041118 |
| CA 2546002 | A1 | 20050616 | CA 2004-2546002 | 20041118 |
| EP 1709011 | A1 | 20061011 | EP 2004-819600 | 20041118 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU | | | | |
| CN 1882549 | A | 20061220 | CN 2004-80034287 | 20041118 |
| BR 2004016817 | A | 20070306 | BR 2004-16817 | 20041118 |
| JP 2007513087 | T | 20070524 | JP 2006-540337 | 20041118 |
| SG 150534 | A1 | 20090330 | SG 2009-1198 | 20041118 |
| US 20080249099 | A1 | 20081009 | US 2006-595882 | 20060517 |
| IN 2006DN02810 | A | 20070803 | IN 2006-DN2810 | 20060518 |
| MX 2006005686 | A | 20060817 | MX 2006-5686 | 20060519 |
| ZA 2006004076 | A | 20070926 | ZA 2006-4076 | 20060519 |
| KR 2006111532 | A | 20061027 | KR 2006-710200 | 20060525 |
| NO 2006002892 | A | 20060809 | NO 2006-2892 | 20060620 |
| PRIORITY APPLN. INFO.: | | | EP 2003-78650 | A 20031120 |
| | | | WO 2004-EP13162 | W 20041118 |


OTHER SOURCE(S): CASREACT 143:60002; MARPAT 143:60002

IT 854397-87-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 7-phenylalkyl substituted 2-quinolinones and
2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)

RN 854397-87-8 ZCPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-(hydroxyphenylmethyl)- (CA INDEX NAME)




IT 130347-24-9P 854397-78-7P 854397-82-3P
854397-84-5P 854397-90-3P 854397-92-5P
854397-94-7P 854398-00-8P 854398-02-0P
854398-05-3P 854398-09-7P 854398-13-3P
854398-17-7P 854398-21-3P 854398-25-7P
854398-28-0P 854398-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-phenylalkyl substituted 2-quinoxalinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)


RN 130347-24-9 ZCAPLUS

CN 2(1H)-Quinoxalinone, 7-[1H-imidazol-1-yl[4-(1-methylethyl)phenyl]methyl]-3-methyl- (CA INDEX NAME)



RN 854397-78-7 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-[2-(1H-imidazol-1-yl)-2-phenylethyl]- (CA INDEX NAME)




RN 854397-82-3 ZCAPLUS

CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(4-[(2-methoxyethyl)amino]-1-piperidinyl]phenylmethyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 854397-81-2

CMF C25 H32 N4 O2




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 854397-84-5 ZCPLUS
CN 2(1H)-Quinolinone, 7-[3-(dimethylamino)-1-phenylpropyl]-3-methyl- (CA INDEX NAME)




RN 854397-90-3 ZCPLUS
CN 2(1H)-Quinolinone, 7-[(4-chlorophenyl)-1-piperidinylmethyl]-3-ethyl- (CA INDEX NAME)



RN 854397-92-5 ZCPLUS
CN 4-Piperidinecarboxylic acid, 1-[(4-chlorophenyl)(2-ethyl-3,4-dihydro-3-oxo-6-quinoxalinyl)methyl]-, ethyl ester (CA INDEX NAME)




RN 854397-94-7 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-(1-pyrrolidinyl)ethyl]-3-ethyl- (CA INDEX NAME)



RN 854398-00-8 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-[[3-[methyl(phenylmethyl)amino]propyl]amino]phenylmethyl-, ethanedioate (1:1)
 (CA INDEX NAME)

CM 1

CRN 854397-99-2
 CMF C28 H32 N4 O




CM 2


CRN 144-62-7
 CMF C2 H2 O4




RN 854398-02-0 ZCPLUS
CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-ethyl- (CA INDEX NAME)




RN 854398-05-3 ZCPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-7-(2-hydroxy-2-phenylethyl)- (CA INDEX NAME)




RN 854398-09-7 ZCPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(3-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854398-13-3 ZCPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(2-fluorophenyl)-1H-imidazol-1-ylmethyl]- (CA INDEX NAME)




RN 854398-17-7 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(phenyl-1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)




RN 854398-21-3 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl]-3-ethyl- (CA INDEX NAME)




RN 854398-25-7 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(phenyl-3-pyridinylmethyl)- (CA INDEX NAME)




RN 854398-28-0 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(phenyl-1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 854398-32-6 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(4-fluorophenyl)-1H-imidazol-1-ylmethyl]-
 (CA INDEX NAME)




IT 130346-67-7 130346-70-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of 7-phenylalkyl substituted 2-quinolinones and
 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)
 RN 130346-67-7 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-methyl-
 (CA INDEX NAME)




RN 130346-70-2 ZCPLUS
 CN 2(1H)-Quinoxalinone, 3-ethyl-7-(1H-imidazol-1-ylphenylmethyl)- (CA INDEX
 NAME)




IT 854398-62-2P 854398-71-3P 854398-92-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 7-phenylalkyl substituted 2-quinolinones and
2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)
RN 854398-62-2 ZCPLUS
CN 2(1H)-Quinoxalinone, 7-benzoyl-3-ethyl- (CA INDEX NAME)



RN 854398-71-3 ZCPLUS
CN 2(1H)-Quinoxalinone, 3-ethyl-7-[(methylsulfonyl)oxy]phenylmethyl- (CA
INDEX NAME)



RN 854398-92-8 ZCPLUS
CN 2(1H)-Quinolinone, 7-[3-(dimethylamino)-1-phenyl-1-propen-1-yl]-3-methyl-
(CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:523424 ZCPLUS <<LOGINID::20090907>>
DOCUMENT NUMBER: 143:60001
TITLE: Preparation of 6-alkenyl and 6-phenylalkyl substituted
2-quinolinones and 2-quinoxalinones as
poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Mabire, Dominique Jean-pierre; Guillemont, Jerome

Emile Georges; Van Dun, Jacobus Alphonsus Josephus;
 Somers, Maria Victorina Francisca; Wouters, Walter
 Boudewijn Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 102 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| WO 2005054201 | A1 | 20050616 | WO 2004-EP131363 | 20041118 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004295058 | A1 | 20050616 | AU 2004-295058 | 20041118 |
| CA 2546300 | A1 | 20050616 | CA 2004-2546300 | 20041118 |
| EP 1687277 | A1 | 20060809 | EP 2004-819601 | 20041118 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| CN 1882547 | A | 20061220 | CN 2004-80034176 | 20041118 |
| BR 2004016206 | A | 20061226 | BR 2004-16206 | 20041118 |
| JP 2007511574 | T | 20070510 | JP 2006-540338 | 20041118 |
| SG 150533 | A1 | 20090330 | SG 2009-1197 | 20041118 |
| US 20070072842 | A1 | 20070329 | US 2006-595891 | 20060518 |
| IN 2006DN02813 | A | 20070803 | IN 2006-DN2813 | 20060518 |
| MX 2006005687 | A | 20060817 | MX 2006-5687 | 20060519 |
| ZA 2006004075 | A | 20070926 | ZA 2006-4075 | 20060519 |
| KR 2006115393 | A | 20061108 | KR 2006-710201 | 20060525 |
| NO 2006002894 | A | 20060809 | NO 2006-2894 | 20060620 |
| PRIORITY APPLN. INFO.: | | | WO 2003-EP13028 | A 20031120 |
| | | | EP 2003-78860 | A 20031205 |
| | | | WO 2003-EP130 | A 20031120 |
| | | | WO 2004-EP13163 | W 20041118 |

OTHER SOURCE(S): CASREACT 143:60001; MARPAT 143:60001
IT 854534-70-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and
 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors)
RN 854534-70-6 ZCAPLUS
CN 2(1H)-Quinoxalinone, 7-[2-(4-chlorophenyl)-2-oxoethyl]-3-ethyl- (CA INDEX
 NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 8 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2000:527827 ZCPLUS <>LOGINID::20090907>>
 DOCUMENT NUMBER: 134:162992
 TITLE: Synthesis and antimicrobial activities of some novel
 quinoxalinone derivatives
 AUTHOR(S): Ali, M. M.; Ismail, M. M. F.; El-Gaby, M. S. A.;
 Zahran, M. A.; Ammar, Y. A.
 CORPORATE SOURCE: Dep. of Chemistry, Faculty of Science, Al-Azhar Univ.,
 Cairo, 11884, Egypt
 SOURCE: Molecules [online computer file] (2000), 5(6), 864-873
 CODEN: MOLEFW; ISSN: 1420-3049
 URL: <http://www.mdpi.org/molecules/papers/50600864.pdf>
 PUBLISHER: Molecular Diversity Preservation International
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:162992
 IT 325469-52-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antimicrobial activities of quinoxalinone derivs.)
 RN 325469-52-1 ZCPLUS
 CN 2(1H)-Quinoxalinone, 7-benzoyl-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS
 RECORD (35 CITINGS)
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 10 ZCPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1992:592207 ZCPLUS <>LOGINID::20090907>>
 DOCUMENT NUMBER: 117:192207
 ORIGINAL REFERENCE NO.: 117:33223a,33226a
 TITLE: Fluorine-19 NMR studies on the mechanism of riboflavin
 synthase. Synthesis of
 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and
 6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine
 Cushman, Mark; Patel, Hemantkumar H.; Scheuring,
 Johannes; Bacher, Adelbert
 CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette,
 IN, 47907, USA
 SOURCE: Journal of Organic Chemistry (1992), 57(21), 5630-43
 DOCUMENT TYPE: Journal

LANGUAGE: English
IT 143309-80-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 143309-80-2 ZCPLUS
CN 2(1H)-Quinoxalinone, 7-benzoyl-3-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)